1First Clinical Medical College, Guangdong Medical University, Zhanjiang 524000, China; 2Shanghai Key Laboratory of Artificial Intelligence for Medical Image and Knowledge Graph, Shanghai 200050, China; 3Department of Radiation oncology, Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China; 4Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China
Abstract：Hypothyroidism is a common complication in patients with nasopharyngeal carcinoma after radiotherapy, and its incidence is mainly associated with clinical factors, such as radiotherapy, chemotherapy, sex, age and clinical stage, etc. The normal tissue complication probability models of radiation-induced hypothyroidism can be established by using related factors, which can be employed to screen the high-risk patients. In this article, clinical factors related to radiation-induced hypothyroidism were summarized, aiming to prevent the early radiation-induced hypothyroidism, reduce the incidence of hypothyroidism and improve the quality of life of patients.
Zhou Ling,Chen Jia,Tao Changjuan et al. Research progress on radiation-induced hypothyroidism in nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(5): 523-526.
[1] Chen YP, Chan A, Le QT, et al. Nasopharyngeal carcinoma[J]. Lancet, 2019, 394(10192):64-80. DOI:10.1016/S0140-6736(19)30956-0. [2] Fan CY, Lin CS, Chao HL, et al. Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy:a population-based cohort study[J]. Radiother Oncol, 2017, 123(3):394-400. DOI:10.1016/j.radonc.2017.04.025. [3] Chaker L, Bianco AC, Jonklaas J, et al. Hypothyroidism[J]. Lancet, 2017, 390(10101):1550-1562. DOI:10.1016/S0140-6736(17)30703-1. [4] Beck-Peccoz P, Rodari G, Giavoli C, et al. Central hypothyroidism-a neglected thyroid disorder[J]. Nat Rev Endocrinol, 2017, 13(10):588-598. DOI:10.1038/nrendo.2017.47. [5] Persani L. Clinical review:central hypothyroidism:pathogenic, diagnostic, and therapeutic challenges[J]. J Clin Endocrinol Metab, 2012, 97(9):3068-3078. DOI:10.1210/jc.2012-1616. [6] Carlé A, Pedersen IB, Knudsen N, et al. Gender differences in symptoms of hypothyroidism:a population-based DanThyr study[J]. Clin Endocrinol, 2015, 83(5):717-725. DOI:10.1111/cen.12787. [7] Floriani C, Gencer B, Collet TH, et al. Subclinical thyroid dysfunction and cardiovascular diseases:2016 update[J]. Eur Heart J, 2018, 39(7):503-507. DOI:10.1093/eurheartj/ehx050. [8] Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism:a review[J]. JAMA, 2019, 322(2):153-160. DOI:10.1001/jama.2019.9052. [9] Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality[J]. JAMA, 2010, 304(12):1365-1374. DOI:10.1001/jama.2010.1361. [10] DeGroot LJ. Radiation and thyroid disease[J]. Baillieres Clin Endocrinol Metab, 1988, 2(3):777-791. DOI:10.1016/s0950-351x (88)80065-x. [11] Hancock SL, Mcdougall IR, Constine LS. Thyroid abnormalities after therapeutic external radiation[J]. Int J Radiat Oncol Biol Phys, 1995, 31(5):1165-1170. DOI:10.1016/0360-3016(95)00019-U. [12] Jereczek-Fossa BA, Alterio D, Jassem J, et al. Radiotherapy-induced thyroid disorders[J]. Cancer Treat Rev, 2004, 30(4):369-384. DOI:10.1016/j.ctrv.2003.12.003. [13] Koc M, Capoglu I. Thyroid dysfunction in patients treated with radiotherapy for neck[J]. Am J Clin Oncol,2009,32(2):150-153. DOI:10.1097/COC.0b013e3181845517. [14] Ringash J. Survivorship and quality of life in head and neck cancer[J]. J Clin Oncol, 2015, 33(29):3322-3327. DOI:10.1200/JCO.2015.61.4115. [15] Capozzi LC, Nishimura KC, McNeely ML, et al. The impact of physical activity on health-related fitness and quality of life for patients with head and neck cancer:a systematic review[J]. Br J Sports Med, 2016, 50(6):325-338. DOI:10.1136/bjsports-2015-094684. [16] Felix H, Dupre N, Drape M, et al. Long-term influence of radiotherapy for cancer of larynx on the appearance of myxedema[J]. Lyon Med, 1961, 93:1043-1050. [17] Luo R, Li M, Yang Z, et al. Nomogram for radiation-induced hypothyroidism prediction in nasopharyngeal carcinoma after treatment[J]. Br J Radiol, 2017, 90(1070):20160686. DOI:10.1259/bjr.20160686. [18] Sommat K, Ong WS, Hussain A, et al. Thyroid V40 predicts primary hypothyroidism after intensity modulated radiation therapy for nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2017, 98(3):574-580. DOI:10.1016/j.ijrobp.2017.03.007. [19] Lee V, Chan SY, Choi CW, et al. Dosimetric predictors of hypothyroidism after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma[J]. Clin Oncol (R Coll Radiol), 2016, 28(8):e52-e60. DOI:10.1016/j.clon.2016.05.004. [20] Lertbutsayanukul C, Kitpanit S, Prayongrat A, et al. Validation of previously reported predictors for radiation-induced hypothyroidism in nasopharyngeal cancer patients treated with intensity-modulated radiation therapy, a post hoc analysis from a Phase Ⅲ randomized trial[J]. J Radiat Res, 2018, 59(4):446-455. DOI:10.1093/jrr/rry036. [21] Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 suppl):S10-S19. DOI:10.1016/j.ijrobp.2009.07.1754. [22] Zhai RP, Kong FF, Du CR, et al. Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma:clinical and dosimetric predictors in a prospective cohort study[J]. Oral Oncol, 2017, 68(1):44-49. DOI:10.1016/j.oraloncology.2017.03.005. [23] Xu Y, Shao Z, Tang T, et al. A dosimetric study on radiation-induced hypothyroidism following intensity-modulated radiotherapy in patients with nasopharyngeal carcinoma[J]. Oncol Lett, 2018, 16(5):6126-6132. DOI:10.3892/ol.2018.9332. [24] Huang CL, Tan HW, Guo R, et al. Thyroid dose-volume thresholds for the risk of radiation-related hypothyroidism in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy-a single-institution study[J]. Cancer Med, 2019, 8(16):6887-6893. DOI:10.1002/cam4.2574. [25] Lin Z, Wu VW, Lin J, et al. A longitudinal study on the radiation-induced thyroid gland changes after external beam radiotherapy of nasopharyngeal carcinoma[J]. Thyroid, 2011, 21(1):19-23. DOI:10.1089/thy.2010.0229. [26] Huang S, Wang X, Hu C, et al. Hypothalamic-pituitary-thyroid dysfunction induced by intensity-modulated radiotherapy (IMRT) for adult patients with nasopharyngeal carcinoma[J]. Med Oncol, 2013, 30(4):710. DOI:10.1007/s12032-013-0710-9. [27] Lin Z, Wang X, Xie W, et al. Evaluation of clinical hypothyroidism risk due to irradiation of thyroid and pituitary glands in radiotherapy of nasopharyngeal cancer patients[J]. J Med Imaging Radiat Oncol, 2013, 57(6):713-718. DOI:10.1111/1754-9485.12074. [28] Bhandare N, Kennedy L, Malyapa RS, et al. Primary and central hypothyroidism after radiotherapy for head-and-neck tumors[J]. Int J Radiat Oncol Biol Phys, 2007, 68(4):1131-1139. DOI:10.1016/j.ijrobp.2007.01.029. [29] Luo R, Wu V, He B, et al. Development of a normal tissue complication probability (NTCP) model for radiation-induced hypothyroidism in nasopharyngeal carcinoma patients[J]. BMC Cancer, 2018, 18(1):575. DOI:10.1186/s12885-018-4348-z. [30] Ratnasingam J, Karim N, Paramasivam SS, et al. Hypothalamic pituitary dysfunction amongst nasopharyngeal cancer survivors[J]. Pituitary, 2015, 18(4):448-455. DOI:10.1007/s11102-014-0593-6. [31] Gupta T, Agarwal J, Jain S, et al. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck:a randomized controlled trial[J]. Radiother Oncol, 2012, 104(3):343-348. DOI:10.1016/j.radonc.2012.07.001. [32] Diaz R, Jaboin JJ, Morales-Paliza M, et al. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer[J]. Int J Radiat Oncol Biol Phys, 2010, 77(2):468-476. DOI:10.1016/j.ijrobp.2009.05.018. [33] Murthy V, Narang K, Ghosh-Laskar S, et al. Hypothyroidism after 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy for head and neck cancers:prospective data from 2 randomized controlled trials[J]. Head Neck, 2014, 36(11):1573-1580. DOI:10.1002/hed.23482. [34] Vogelius IR, Bentzen SM, Maraldo MV, et al. Risk factors for radiation-induced hypothyroidism:a literature-based meta-analysis[J]. Cancer, 2011, 117(23):5250-5260. DOI:10.1002/cncr.26186. [35] Rønjom MF, Brink C, Bentzen SM, et al. Hypothyroidism after primary radiotherapy for head and neck squamous cell carcinoma:normal tissue complication probability modeling with latent time correction[J]. Radiother Oncol, 2013, 109(2):317-322. DOI:10.1016/j.radonc.2013.06.029. [36] Boomsma MJ, Bijl HP, Christianen ME, et al. A prospective cohort study on radiation-induced hypothyroidism:development of an NTCP model[J]. Int J Radiat Oncol Biol Phys, 2012, 84(3):e351-e356. DOI:10.1016/j.ijrobp.2012.05.020. [37] Zhou L, Chen J, Shen W, et al. Thyroid V (50) is a risk factor for hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy:a retrospective study[J]. Radiat Oncol,2020,15(1):68. DOI:10.1186/s13014-020-01490-x.
2021, Vol. 30 
